Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My thoughts on the changes of this company along with no real interest in developing existing/past XCUR technology with NWU is that they may form a distribution point. South Korean involvement is a sincere thought?
See what I mean about them trying to keep the share price at a $buck to maintain on the Nasdaq. I just don't trust these new guys running XCUR so I would think a fluffy PR will be due soon but maybe not. I can't help but think the new company had no clue about the development contract with North Western University. Not sure but believe we will see this drop much further for those who would like to buy in again. I may but need to do the math since I stayed through that nasty RS we had. We still need to see a better plan and stated in English before I lay out more money for shares plus the talks referencing XCUR obligations with NWU. I sure hated to see our technologies hit the bricks along with all the many Institution Investors and investments.
Rabbit out of the hat harder than the rug pull
It is hard to believe old management collapsed the company but they did however these new guys that decided to buy the company are from the Far East and that is fine but these guys had no idea the potential of all our workings or did they? At any rate these guys had no clue on what XCUR must do under existing contract with NW University. Seems like we have a bunch of rookies running this company. Now it is only my opinion that they (management) are trying real hard to keep the stock at least at the $1 mark for NASDAQ requirements but I believe that will fail in due time unless the company can pull a real rabbit out of their hat now I said a real rabbit not smoke and mirrors. Lastly yes I am invested here but like many decided to hold through the last RS.
OK, now the weblink below is to a filing late 8-9-23 but I will add that we knew about the non compliance problem with a clear threat pertaining to the Nasdaq listing but now Exicure is in breach of contract involving Northwestern University. This clearly means that the projected share price of .50 may drop much lower. The corporation that bought the Exicure seemingly was clueless of the development responsibilities involving past dealings with Northwestern University. Between the business structure and business plan the last thing Exicure needed was to be in breach of contract.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001698530/000169853023000084/xcur-20230809.htm
Come to me sweetheart drop another 40 cent, I will wait!
It appears these jokers are going to sell all our remaining technology so they can continual their journey on being nothing more than a shell company waiting for one of their friends to reverse merge with us. I doubt very much if it will be a merge but rather a reverse merger. It is hard to believe that Exicure as we knew it 3 years ago could fall into this environment, just unreal plus all our patents technology and contacts mean nothing to new management. So let us watch these guys pay the leasing on that 30,000 square foot building by selling all our technology to whoever. It appears that the private company we invested that $1,000,000.00 in might be the private entity that "might" RM with us. Other thoughts are a distribution point needed in the North Eastern region of the USA. At any rate watch and see but feel strongly that we will see .50 share price in the coming months.
Come to me sweetheart .50 share price then we can tall!
Oh no, now I gotta learn how to read and speak Korean.....or whatever? Wasn't I punished enough by previous management?
Damn....you can now count on this dropping down to around your ankles big time!...maybe as low as your toe nails?
Tata boy....come to daddy, drop down to .50 and say you are sorry for that past RS...then, perhaps I will forgive you and buy more shares.
Take it down to .50 cent than it might be worth a handful of my change...I can still feel the blisters from that 1/30 RS months ago. It is amazing someone didn't end up in jail referencing past management.
Thanks for the reply. I know very little about this Company except for the fact that it is lightly traded. I hate when management keeps shareholders in the dark. They are due to file their 10k and I'm sure it is ugly.
Now I'm not saying that something big can happen here but with the noninterest of investors, I have to pass..
I don't know what to think about this except is it possible some private company and Exicure will reverse merge. No way in heck will this (in my opinion) be able to maintain Nasdaq listing unless some type of merger is in the works. I gather the share structure is perfect or setup for this to possibly happen because we are too damn far away to rise high enough in the time span we need before any real (dream) of a product.
I hated the RS we went through and will look at the math in my account as to what share price this needs to fall to make it possible for me to reinvest but with the past fiasco involving past CEO David.... I'm incline to just let what shares I have left sit and hope and poke and not buy in again. At my age I ll probably be gone before I see anything to be excited about like we did in the past.
Sure is a damn shame this up and coming corporations to end up in a crappy fiasco and lose at least 50 institutional investments/investors so be very cautious in jumping back into this and besides the maintenance/lease on our 30,000 sq ft building is going to take a bite out of us. You probably can hear your voice echo on that floor especially losing no less than 50% of their employees but believe that percentage has risen since.
Under the past fiasco I don't think lawsuits were strong enough several should have been arrested and dealt with.
On December 15, 2022, the Company held a Special Meeting of Stockholders (the “Special Meeting”), at which a quorum was present. At the Special Meeting, the stockholders of the Company voted on the following two proposals: (1) to approve the issuance of 3,400,000 newly issued shares of common stock of the Company (“Common Stock”) by the Company to CBI USA, Inc. (“CBI USA”) in a private placement at a price per share of $1.60 (the “Private Placement”), which would result in a “change of control” of the Company under the applicable rules of Nasdaq (“Proposal 1”), and (2) to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the foregoing proposal (“Proposal 2”). The final results of the voting on each proposal are set forth below.
Grab your socks again looks like crap may hit the wall again? https://www.sec.gov/ix?doc=/Archives/edgar/data/1698530/000169853022000064/xcur-20220822.htm
Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
Useless POF ticker will be back under a buck in nothing flat.
Of course like I said prior XCUR is doing a RS but I find it so strange that they didn't determine the reverse split structure in an exactly ratio prior to voting. At any rate those who might be interested....... https://www.sec.gov/ix?doc=/Archives/edgar/data/1698530/000169853022000037/xcur-20220610.htm
Will this bounce around the low? Watch.
XCUR
AH. Their trying so hard to keep it from running up. Don’t think they have the shares they post to do it
Any input on the post (#267) previous to yours regarding the annual meeting, reverse split, etc.? I am confused...
XCUR, here it comes , large insider buying! see here
https://seekingalpha.com/news/3841307-exicure-up-25-pre-market-following-insider-buy
REVERSE SPLIT COMING HERE
https://www.sec.gov/Archives/edgar/data/1698530/000110465922041485/tm2210605-2_pre14a.htm
Yes you're right. Perhaps people are pulling out of the market, Shorts going hard with that downward momentum.
Yes but the previous weeks I’ve had some success. This week just been getting burned hard core
I would say much longer than Week
This play right here sums up how this entire week has been going in the market
Not even a slim chance of a reversal in sight... You'd think it would've found a bottom by now, but then it tanks even further lol...
What a pathetic run. Lol cut short at market open
more buys vs sells today $$$$
Reverse split coming May 27th "1 for every 10" or as much as "1 for every 30" shares.
lete see that .25 pivy $$$$
Exicure AS is 200 million shares and the OS shares are 123 million shares but the "fully diluted" shares are only 89 million what the hell. They should have increased the Authorized Shares. Sure the problem with de-listing to the OTC may have happen in June but what I am seeing is Exicure (as I said prior) absolutely nothing to offer investors to stay. The fully diluted shares are only 89 million so if they are so trigger happy at that figure what are we going to see in the future. We had at one time 149 Institutional Investments in this company and last check a few days ago I believe it was 65 and most likely less by now. They may be able to increase their share price by reversing but again with only 89 million share fully diluted this really sucks big time.
I gather legal actions (because Exicure) has also cost us.
This sucks....Exicure Proxy 1-10 or 1-30 RS, To be voted on May 27, 2022 at 2:00pm Eastern time.
https://www.sec.gov/Archives/edgar/data/1698530/000110465922041485/tm2210605-2_pre14a.htm
In a report released today, Keay Nakae from Chardan Capital reiterated a Hold rating on Exicure (XCUR – Research Report), with a price target of $0.25. The company's shares closed last Monday at $0.20, close to its 52-week low of $0.14. According to TipRanks.com, Nakae is a 4-star analyst with an average return of 11.8% and a 43.0% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Mountain Crest Acquisition II, and Arrowhead Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Exicure.
Exicure Shares Plunge After Q4 Results Included A Going Concern Risk
Normally we would be de-listed on June 28th 2022 but even though management has changed plus our troubles I'm sure we will stay on the Nasadq without de-listing threat until late December 2022 at which time we would be receive notice of de-listing if XCUR hasn't kissed $1 dollar closing share price for 10 business days.
I wonder if any traders are thinking of buying this Monday at rock bottom price and then on June 28, 2022 seeing if Exicure doesn't need the NASDAQ extension because it kissed $1 dollar share price for 10 business days. I would not risk that play as I feel Exicure will file the necessary paperwork and get that 180 day extension (if needed) on June 28th 2022....not bad could mean .80 per share gain in less than 90 days provided we reached $1.00 share price.
It is a continuation of their 2017 employee incentive program with basically registering 4,900,000 shares that were worth .31 cent per share on March 25th 2022.
Here is just the reporting by "Cooley LLP"
https://www.sec.gov/Archives/edgar/data/1698530/000169853022000022/ex51_cooleyopinionfors-8maa.htm
Below is the main S-8 if you wish to read it.
https://www.sec.gov/Archives/edgar/data/1698530/000169853022000022/exicure-formsx8march2022.htm
What does THE S-8 say, didnt Read thru it yet?
What does THE S-8 say, didnt Read thru it yet?
4 pm close basically .26 cent. Now check out the after hours trades over 6 million shares traded and we dropped to .16 and closed around 8pm with brain damage at .19 cent per share.
The S-8 is also embarrassing if you were he when our share price was around $3.25 or so.
Although it dipped to .18 after hours, its interesting that Ihub has XCUR @ .19 while every one else, including my broker, has it @ .26, the price at the close of the regular trading session.
I am very wrong about that...I just read the entire 10-K
On December 10, 2021, the Company announced its commitment to a plan to wind down the Company’s immuno-oncology program for cavrotolimod (AST-008) and the Company’s XCUR-FXN preclinical program for the treatment of Friedreich’s ataxia. The Company intends to realign its research and development resources to support (i) the development of its preclinical program targeting SCN9A for neuropathic pain, (ii) the continued advancement of its partnered programs with Ipsen Biopharm Limited to develop SNA-based treatments in neuroscience targeting Huntington’s disease and Angelman syndrome, (iii) its continued advancement of its partnered program with AbbVie to develop SNA-based treatments for hair loss disorders, as well as (iv) the continued research and development of other undisclosed therapeutic product candidates.
What do you mean, plus about Abbvie too?
You know They paid off all dept last week of 7 Mill out of 40 Mill cash balance. Smallcaps Never do this, specially when running low in cash later in 2022.
So the .31 cents yesterday was referencing the S-8 filed a couple hours ago. I don't think we can even maintain .31 but we shall see?
Followers
|
18
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
294
|
Created
|
05/11/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |